Cascade Prodrug, Inc., founded in Oregon, is a biotechnology firm dedicated to developing innovative prodrug therapies for the treatment of solid tumors and hyper-proliferative diseases. Their core mission is to leverage the unique conditions of the tumor microenvironment to create targeted oncology treatments. The company's primary product pipeline includes CPD100Li, a prodrug activated in low oxygen concentrations found in solid tumors, aiming to improve the efficacy and safety of cancer therapies.
Notable figures associated with Cascade Prodrug include leading scientists and industry experts in oncology and pharmaceutical development. The company has garnered attention from prominent investors in the biotech sector, contributing to its research and development efforts. Key achievements include significant advancements in their prodrug technology and promising preclinical results. Cascade Prodrug's impact lies in its potential to revolutionize cancer treatment by providing more effective and targeted therapeutic options for patients with solid tumors.
CPD100 is Cascade Prodrug's hypoxia-activated vinblastine-N-oxide candidate in development for suprachoroidal treatment of wet age-related macular degeneration.
